Pyoderma Gangrenosum (PG) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033


 Pyoderma gangrenosum (PG) is a rare skin disease characterized by the formation of ulcers on the body, particularly in the pre-tibial area, which often results in unsightly scar tissue. Diagnosis of PG relies primarily on clinical observation since no specific markers are detectable through blood tests or tissue analysis. The underlying causes and mechanisms of PG are not well understood, and current treatments are based on empirical evidence rather than targeted approaches. PG is characterized by recurring painful ulcers on the skin, most commonly found on the pre-tibial region but can appear anywhere on the body, including the trunk, head and neck, upper limbs, and genitalia. Multiple ulcers can co-occur on different anatomical sites, and PG may also manifest in the peristomal area, accounting for a significant proportion of chronic parastomal ulcers. About 50% of PG cases are associated with systemic diseases, while the remaining cases are idiopathic. Inflammatory bowel disease, rheumatoid arthritis, and hematological malignancies are the most commonly linked diseases. There are four distinct classes of PG: ulcerative, pustular, bullous, and vegetative. These classifications aid in recognizing different disease presentations, although variants can overlap. Ulcerative PG, or classic PG, is the most common form, exhibiting the previously described symptoms, and is frequently associated with inflammatory bowel disease, arthritis, or monoclonal gammopathies. Pustular PG is a more superficial variant primarily linked to inflammatory bowel disease. Bullous PG is another superficial form characterized by painful blisters, predominantly on the upper limbs and face, often associated with hematological malignancies. Vegetative PG is usually less aggressive than other variants, progressing slowly with fewer symptoms and generally responding well to milder treatments. Peristomal PG may develop after ileostomy or colostomy in individuals with inflammatory bowel disease, possibly due to the surgical procedure or subsequent irritation by the stoma apparatus or fecal leakage. Currently, there is no specific or targeted therapy for PG, and treatment approaches rely heavily on empirical evidence, considering factors such as the severity and extent of ulceration, associated diseases, and patient characteristics. The primary goals of treatment are to reduce inflammation and pain in the lesions and promote healing.

·       The prevalence of PG, standardized for age and sex, is 5.8 cases per 100,000 adults. Adjusted prevalence rates indicate a nearly two-fold higher occurrence in women (7.1 cases per 100,000) compared to men (4.4 cases per 100,000).

·       The highest standardized prevalence is observed in individuals aged 70 to 79 (9.8 cases per 100,000), with patients aged 50 or older accounting for nearly 70% of all PG cases.

 

Thelansis’s “Pyoderma Gangrenosum (PG) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Pyoderma Gangrenosum (PG) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Pyoderma Gangrenosum (PG) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Pyoderma Gangrenosum (PG) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Pyoderma Gangrenosum (PG) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Pyoderma Gangrenosum (PG), Pyoderma Gangrenosum (PG) market outlook, Pyoderma Gangrenosum (PG) competitive landscape, Pyoderma Gangrenosum (PG) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co
Read more

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Metabolic syndrome refers to a clustering of multiple disorders that collectively increase an individual's susceptibility to atherosclerotic cardiovascular disease, insulin resistance, diabetes mellitus, as well as vascular and neurological complications such as cerebrovascular accidents. The underlying causes of metabolic syndrome typically include excess weight, obesity, a sedentary lifestyle, and genetic predisposition. This syndrome exerts detrimental effects on various body systems. Insulin resistance, a key component of metabolic syndrome, leads to microvascular damage, increasing the risk of endothelial dysfunction, vascular resistance, hypertension, and inflammation of vessel walls. Bariatric surgery is recognized as the most effective standalone therapy for metabolic syndrome. However, patients undergoing this procedure require long-term follow-up to mitigate potential surgical, nutritional, and psychiatric complications. Thelansis’s “Metabolic Syndrome Market Outl
Read more

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Type 1 Diabetes Mellitus (T1D) is characterized as an autoimmune disorder resulting in the autoimmune destruction of insulin-producing pancreatic beta cells. This condition necessitates life-long insulin replacement, administered through multiple daily insulin injections, insulin pump therapy, or an automated insulin delivery system. The absence of insulin can lead to the development of Diabetic Ketoacidosis (DKA), a life-threatening condition. The most common symptoms associated with this disease are polyuria and polydipsia. Effective management of T1D involves: Multiple daily insulin injections Insulin pump therapy An automated insulin delivery system in conjunction with glucose monitoring Continuous Glucose Monitoring (CGM) is the preferred method. However, all individuals with T1D should be capable of performing Blood Glucose Monitoring (BGM) via capillary blood if CGM is not available. Acute complications of diabetes primarily include hypoglycemia and severe
Read more